Hematology-American Society of Hematology Education Program

Article	Citations
Managing toxicities of Bruton tyrosine kinase inhibitors	75
Therapeutic development and current uses of BCL-2 inhibition	61
Bispecifics, trispecifics, and other novel immune treatments in myeloma	37
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors	36
Platelet transfusion refractoriness: how do I diagnose and manage?	35
Updates in infection risk and management in acute leukemia	34
Preventing infections in children and adults with asplenia	33
Monoclonal gammopathies of clinical significance	32
Management of AL amyloidosis in 2020	31
Therapy for lower-risk MDS	30
Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes	29
Next-generation cell therapies: the emerging role of CAR-NK cells	25
Inferior vena cava filters: a framework for evidence-based use	25
Gene therapy for hemophilia	24
Updates in chronic graft-versus-host disease	23
Management of Waldenström macroglobulinemia in 2020	23
Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review	22
Have we reached a molecular era in myelodysplastic syndromes?	22
Future of CAR T cells in multiple myeloma	21
Outpatient transfusions for myelodysplastic syndromes	21
Advances in the management of α-thalassemia major: reasons to be optimistic	20
“TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry	20
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia	20
Does ABO and RhD matching matter for platelet transfusion?	20
Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics	19

Combining antiplatelet and anticoagulant therapy in cardiovascular disease	18
Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?	18
Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic di	18
Dyskeratosis congenita and telomere biology disorders	18
Allogeneic hematopoietic cell transplantation for older patients	17
Gene therapy for sickle cell disease: where we are now?	17
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?	17
What to use to treat AML: the role of emerging therapies	17
Identifying potential germline variants from sequencing hematopoietic malignancies	16
Modern management of Fanconi anemia	16
Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes	16
Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)	16
Management of heavy menstrual bleeding on anticoagulation	15
High-risk multiple myeloma: how to treat at diagnosis and relapse?	15
Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management	15
Optimizing the management of chronic pain in sickle cell disease	15
Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings	14
Challenges in chronic transfusion for patients with thalassemia	14
Double-hit lymphoma: optimizing therapy	14
Does aspirin prevent venous thromboembolism?	13
How do we sequence therapy for marginal zone lymphomas?	13
Women and bleeding disorders: diagnostic challenges	13
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	13
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms	13
Relapsed ALL: CAR T vs transplant vs novel therapies	13
Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs	12
Blast and accelerated phase CML: room for improvement	12
Evidence-Based Minireview: Abnormal uterine bleeding in users of rivaroxaban and apixaban	12
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop	12
Epidemiology and treatment of priapism in sickle cell disease	12
Transformed lymphoma: what should I do now?	12
Chemotherapy-free frontline therapy for CLL: is it worth it?	12
Hemophilia gene therapy: ushering in a new treatment paradigm?	12
How to recognize and manage COVID-19-associated coagulopathy	12
How to manage CML patients with comorbidities	12
How to avoid the problem of erythrocyte alloimmunization in sickle cell disease	11
Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP	11
COVID-19 and thrombosis: searching for evidence	11
Antibodies and bispecifics for multiple myeloma: effective effector therapy	11
Inherited microcytic anemias	11
Diamond-Blackfan anemia	11
Global look at nutritional and functional iron deficiency in infancy	11
Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency	11
Mechanisms of somatic transformation in inherited bone marrow failure syndromes	11
Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management	11
Indications for transfusion in the management of sickle cell disease	11
Approach to the patient with suspected hypereosinophilic syndrome	11
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	11
Extrahematopoietic manifestations of the short telomere syndromes	11
Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life	10

Direct oral anticoagulant (DOAC) interference in hemostasis assays	10
Achieving MRD negativity in AML: how important is this and how do we get there?	10
Lower risk but high risk	10
Cellular therapy for multiple myeloma: what's now and what's next	10
When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)?	10
Heparin-induced thrombocytopenia and cardiovascular surgery	10
Genomics of MPN progression	10
Sequencing multiple myeloma therapies with and after antibody therapies	10
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	10
Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas	10
When does a PNH clone have clinical significance?	9
How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation	9
Molecular prognostication in Ph-negative MPNs in 2022	9
How immunodeficiency can lead to malignancy	9
Hematology 2022—what is complete HLA match in 2022?	9
Novel targets in aggressive lymphoma	9
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	9
CAR T cells vs allogeneic HSCT for poor-risk ALL	9
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy	9
How do I sequence therapy for follicular lymphoma?	8
Sequencing therapy in relapsed DLBCL	8
How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia	8
Evidence-Based Minireview: Treatment of relapsed chronic lymphocytic leukemia after venetoclax	8
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	8
Passive immune therapies: another tool against COVID-19	8
Approaches for relapsed CLL after chemotherapy-free frontline regimens	8
Minimal residual disease in multiple myeloma: why, when, where	8
A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact	7
Transplantation in CML in the TKI era: who, when, and how?	7
Transplant for TP53-mutated MDS and AML: because we can or because we should?	7
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies	7
How to evaluate and treat the spectrum of TMA syndromes in pregnancy	7
Role of venous stenting for venous thromboembolism	7
Factor-mimetic and rebalancing therapies in hemophilia A and B: the end of factor concentrates?	7
New approaches to tackle cytopenic myelofibrosis	7
Lifelong TKI therapy: how to manage cardiovascular and other risks	7
CNS prophylaxis in aggressive B-cell lymphoma	7
The clinical and laboratory evaluation of patients with suspected hypocellular marrow failure	7
In 2022, which is preferred: haploidentical or cord transplant?	7
How well do platelets prevent bleeding?	7
AL amyloidosis: untangling new therapies	7
Harnessing lymphoma epigenetics to improve therapies (article not eligible for CME credit)	6
Strategies for aggressive T-cell lymphoma: divide and conquer	6
Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?	6
Diagnosis and clinical management of red cell membrane disorders	6
Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?	6
Unexplained arterial thrombosis: approach to diagnosis and treatment	6
Management of hemolytic transfusion reactions	6
Rebalanced hemostasis in liver disease: a misunderstood coagulopathy	6
Incorporating gonadal health counseling into pediatric care of sickle cell patients	6
Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?	6
When I treat a patient with acute pulmonary embolism at home	6
Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?	6
Clinical screening for Ph-like ALL and the developing role of TKIs	6
Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma	6
What else do I need to worry about when treating graft-versus-host disease?	6
Evidence-Based Minireview: Should all newly diagnosed MM patients receive CD38 antibody–based treatment?	6
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map	6
The consultant's guide to smoldering multiple myeloma	5
Treatment of CML in pregnancy	5
Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease	5
Risk stratifying MDS in the time of precision medicine	5
Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?	5
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	5
Treatment of Richter's syndrome	5
Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem	5
Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia	5
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents	5
Applied genomics in MPN presentation	5
Targeting inflammation in lower-risk MDS	5
Prevention and management of venous thromboembolism in pregnancy: cutting through the practice variation	5
CAR T cells for other pediatric non–B-cell hematologic malignancies	5
Frontline treatment in CLL: the case for time-limited treatment	5
Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy	5
Optimizing management of acute leukemia in community centers and when to refer	5
Leukemogenesis in infants and young children with trisomy 21	5
Transplant in AML with measurable residual disease: proceed or defer?	5
Evidence-Based Minireview: Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism	5
Minimizing cardiac toxicity in children with acute myeloid leukemia	5
Management of TKI-resistant chronic phase CML	5

Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?	5
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies	5
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	5
What factors guide treatment selection in mycosis fungoides and Sezary syndrome?	5
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients	4
Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?	4
Clinical trial considerations in sickle cell disease: patient-reported outcomes, data elements, and the stakeholder engagement framework	4
Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation	4
Treatment of older adult or frail patients with multiple myeloma	4
Fitness and frailty in myeloma	4
Psychosocial and financial issues after hematopoietic cell transplantation	4
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	4
Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism	4
Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease	4
Noninfectious lung complications of hematopoietic cell transplantation	4
Warm autoimmune hemolytic anemia and the best treatment strategies	4
New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT)	4
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy	4
Evidence-Based Minireview: What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?	4
Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy	4
Optimizing management of sickle cell disease in patients undergoing surgery	4
Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies	4
Management of marginal zone lymphomas	4
Understanding neutropenia secondary to intrinsic or iatrogenic immune dysregulation	4
Genetics of severe congenital neutropenia as a gateway to personalized therapy	4
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia	4
Diagnosis and clinical management of enzymopathies	4
Treatment dilemmas: strategies for priapism, chronic leg ulcer disease, and pulmonary hypertension in sickle cell disease	3
Oral hypomethylating agents: beyond convenience in MDS	3
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	3
TKI discontinuation in CML: how do we make more patients eligible? How do we increase the chances of a successful treatment-free remission?	3
Evidence-Based Minireview: Molecular precision and clinical uncertainty: should molecular profiling be routinely used to guide risk stratification in MDS?	3
Evidence-Based Minireview: The use of premedications for platelet transfusions in pediatric patients	3
What have we learned about the patient's experience of von Willebrand disease? A focus on women	3
How do we optimally utilize factor concentrates in persons with hemophilia?	3
Perioperative hemostasis for patients with hemophilia	3
Special considerations in GI bleeding in VWD patients	3
Ph+ ALL in 2022: is there an optimal approach?	3
When to worry about inherited bone marrow failure and myeloid malignancy predisposition syndromes in the setting of a hypocellular marrow	3
Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond	3
Selecting initial therapy in CLL	3
Platelet components and bacterial contamination: hospital perspective 2022	3
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	3
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	3
Long-term prophylaxis: what are our options and how to define success?	3
Can we use epigenetics to prime chemoresistant lymphomas?	3
Managing therapy-associated neurotoxicity in children with ALL	3
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts	3
Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?	3
Does MRD have a role in the management of iNHL?	3
Modified T cells as therapeutic agents	3
Acute GVHD: think before you treat	3
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease	3